A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
Part of paid clinical trials in Montgomery, Alabama.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT01621178
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Dulaglutide — DRUGAdministered SC
- Insulin glargine — DRUGAdministered SC
- Insulin lispro — DRUGAdministered SC
Study Details
The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease.
Key Dates
- Start date
- Jul 31, 2012
- Status verified
- Sep 2019
- Primary completion
- Jun 30, 2016
- Completion
- Dec 31, 2016
Study Design
- Enrollment
- 577 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Insulin glargineInsulin glargine was administered subcutaneously (SC) at bedtime per a modified forced-titration treat-to-target algorithm. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
- Experimental: 0.75 mg Dulaglutide0.75 milligram (mg) of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
- Experimental: 1.5 mg Dulaglutide1.5 mg of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
Primary Outcome Measure
Change From Baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline, 26 Weeks ]
Locations (47)
Find similar trials in Montgomery, AL
By condition
Related Studies
- Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)Recruiting · Johns Hopkins Bloomberg School of Public Health · Kansas City, Missouri
- Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal CenterRecruiting · University of Michigan · Ann Arbor, Michigan
- Senescence in Chronic Kidney DiseasePHASE2 · Enrolling By Invitation · Mayo Clinic · Jacksonville, Florida
- A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisPHASE3 · Recruiting · Amgen · Los Angeles, California